MAP2K1 and prostate cancer: For instance, co-administration of the SMO inhibitor SANT-1 with the MEK1 inhibitor PD325901 in prostate cancer cells characterized by hyperactivation of MAPK signaling, has been shown to reduce prostate cancer cell growth more than either single agent alone (Gioeli et al., 2011).